Question Bank › Small reported base, oversized already-contracte

Small reported base, oversized already-contracted forward commitments

Calls Tested
1,498
Answered YES
59
Hit Rate
3.9%
rare by design

Surmodics, Inc. (SRDX) — this company's answers

NO on the Q3 2018 call 2018-08-06 A
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录,判断管理层是否描述了未来业务,这些业务是对方已经承诺的(如已签合同、确定订单、授予项目、承诺量、积压订单或已同意扩展),且管理层将其描述为相对于公司当前报告的业务水平而言规模很大,并预计在接下来一年左右开始或继续转化为实际收入或活动。 检查要点: (a) 已承诺的业务:是否有已签署的合同或协议?例如,与Abbott的SurVeil协议,这是已签署的全球商业化权利协议,包括供应和合作。但这是否是“未来业务”?该协议已产生收入(本季度1.7百万美元),且未来有更多收入(递延收入)。但这是否是“已承诺”的?是的,协议已签署。但管理层是否将其描述为“大”相对于当前业务?公司总收入约2200万美元/季度,年化约8800万美元。Abbott协议带来的收入预计全年400-450万美元,占比较小(约5%)。所以不算“大”。另外,Embolitech收购是已完成的,但那是收购,不是未来业务承诺。其他产品如.014、.018球囊等,还在寻找合作伙伴,未签约。所以没有其他已承诺的大业务。 (b) 管理层是否强调其规模?没有,只是提到收入增长,但未说“大”或“记录”。 (c) 是否近期且大部分尚未实现?Abbott收入已开始,但规模不大。 因此,答案应为NO。注意:管理层提到“我们正在与多个感兴趣方进行商业协议”,但那是谈判中,不是已承诺。所以不符合。 最终答案:NO。

← Back to the full SRDX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management describe FUTURE BUSINESS THAT COUNTERPARTIES HAVE ALREADY COMMITTED TO THE COMPANY — signed contracts, firm orders, awarded programs, committed volumes, backlog, or agreed expansions, in whatever form fits the industry — that management itself presents as LARGE RELATIVE TO THE COMPANY'S CURRENT REPORTED LEVEL OF BUSINESS, with conversion into actual revenue or activity expected to begin or continue within roughly the coming year? Answer YES when management's own words convey ALL of: (a) the forward business is already secured — decided and committed by the counterparty, not pipeline, bids, negotiations, or hoped-for demand; (b) management conveys the disproportion in its own framing — comparing it to current revenue or activity, calling it record or unprecedented for the company, or describing the expansion, hiring, or preparation now required to deliver it; and (c) the contribution is near-dated and mostly still ahead of the results just reported, so today's numbers understate the business already captured. Answer NO if the forward story rests on demand strength, market opportunity, pipeline, or deals still being negotiated. NO if the committed business is routine in size for this company or is ordinary backlog worked off at the usual pace. NO if conversion is distant, undated, or contingent on approvals, financing, or decisions not yet made. NO if management is chiefly explaining delays or cancellations of previously committed business. NO if the disproportion appears only in an analyst's model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
AIP Arteris, Inc. Q1 2024 2024-05-04 A
KOPN Kopin Corporation Q4 2023 2024-03-14 C+
HSAI Hesai Group Q4 2023 2024-03-12 D
EFXT Enerflex Ltd. Q3 2023 2023-11-09 C+
MAC The Macerich Company Q3 2023 2023-10-31 D
EVLV Evolv Technologies Holdings, Inc. Q2 2023 2023-08-10 B+
TGLS Tecnoglass Inc. Q2 2023 2023-08-08 A
OSK Oshkosh Corporation Q2 2023 2023-08-01 B+
NXT Nextracker Inc. Q1 2024 2023-07-28 C+
USAP Universal Stainless & Alloy Products, In Q2 2023 2023-07-26 B
DLR Digital Realty Trust, Inc. Q4 2022 2023-02-16 C+
ROAD Construction Partners, Inc. Q1 2023 2023-02-10 A
FLNC Fluence Energy, Inc. Q1 2023 2023-02-09 B+
ACLS Axcelis Technologies, Inc. Q4 2022 2023-02-09 A
SMRT SmartRent, Inc. Q3 2022 2022-11-13 B
PFMT Performant Financial Corporation Q3 2022 2022-11-12 C
BEEM Beam Global Q3 2022 2022-11-10 C+
TT Trane Technologies plc Q3 2022 2022-11-02 A
PLOW Douglas Dynamics, Inc. Q3 2022 2022-11-01 B+
FSLR First Solar, Inc. Q3 2022 2022-10-28 C+
RDI Reading International, Inc. Q2 2022 2022-08-14 C
CMAX CareMax, Inc. Q2 2022 2022-08-13 C
EVGO EVgo, Inc. Q2 2022 2022-08-09 C+
UUUU Energy Fuels Inc. Q2 2022 2022-08-09 C
CRL Charles River Laboratories International Q2 2022 2022-08-03 C
SYM Symbotic Inc. Q3 2022 2022-08-01 B+
VNRX VolitionRx Limited Q1 2022 2022-05-12 F
NSIT Insight Enterprises, Inc. Q1 2022 2022-05-08 A
KTCC Key Tronic Corporation Q3 2022 2022-05-07 C
JCI Johnson Controls International plc Q2 2022 2022-05-04 C
VSH Vishay Intertechnology, Inc. Q1 2022 2022-05-03 B
SILC Silicom Ltd. Q1 2022 2022-04-30 B+
ADSE ADS-TEC Energy PLC Q4 2021 2022-04-28 D
VALN Valneva SE Q4 2021 2022-03-24 C
FAT FAT Brands Inc. Q4 2021 2022-03-21 F
CDMO Avid Bioservices, Inc. Q3 2022 2022-03-08 B+
CMT Core Molding Technologies, Inc. Q4 2021 2022-03-08 C+
STN Stantec Inc. Q4 2021 2022-02-27 A
AMAT Applied Materials, Inc. Q1 2022 2022-02-16 B+
FLUX Flux Power Holdings, Inc. Q2 2022 2022-02-10 D
PLUS ePlus inc. Q3 2022 2022-02-03 C+
GFS GLOBALFOUNDRIES Inc. Q3 2021 2021-11-30 A
PNR Pentair plc Q3 2021 2021-10-26 C+
GDS GDS Holdings Limited Q2 2021 2021-08-17 C+
AGYS Agilysys, Inc. Q1 2022 2021-07-27 A
DOV Dover Corporation Q2 2021 2021-07-20 B+
BKYI BIO-key International, Inc. Q3 2018 2018-11-15 D
TPIC TPI Composites, Inc. Q3 2018 2018-11-11 C
PRIM Primoris Services Corporation Q2 2018 2018-08-11 C+
FTK Flotek Industries, Inc. Q2 2018 2018-08-08 F
NPO EnPro Industries, Inc. Q2 2018 2018-08-02 C
MVIS MicroVision, Inc. Q2 2018 2018-07-31 D
FSS Federal Signal Corporation Q1 2018 2018-05-12 A
CG The Carlyle Group Inc. Q1 2018 2018-05-04 B
CPK Chesapeake Utilities Corporation Q3 2017 2017-11-10 A
LEA Lear Corporation Q2 2017 2017-07-26 B+
VSAT Viasat, Inc. Q4 2017 2017-05-23 C+
TGEN Tecogen Inc. Q2 2016 2016-08-10 C+
GOGO Gogo Inc. Q1 2016 2016-05-06 C+

How the model reasoned

VALN · Q4 2021 → YESThe question is about whether management describes future business that counterparties have already committed to, that's large relative to current business, and expected soon. NO The transcript shows management referencing existing purchase agreements and specific deliveries (e.g., 24.3 million doses in Q2-Q3 2022), but the overall 2022 revenue guidance explicitly includes both existing agreements and anticipated new contracts to be concluded over the coming months. The "up to" structure and 2022-2023 timeline indicate that not all volume is firmly committed and secured today, with some elements still in negotiation or pipeline. Management does not frame the full guidance range as already-decided and disproportionate in a way that excludes future deals; instead, it presents the range as incorporating both secured and expected additional contracts.
EVLV · Q2 2023 → YESThe question is about whether management describes future business that counterparties have already committed to, that's large relative to current business, with conversion expected soon. YES The transcript explicitly presents RPO of $198.3 million as a record high, up 145% year-over-year and 23% sequentially, and frames it as committed future revenue from existing contracts. Management contrasts this with current quarterly revenue of $19.8 million and ARR of $54 million, stating 2023 ARR will more than double from $34 million at the end of 2022 to $70-72 million. They note subscriptions growing to 4,500 by year-end from 3,386, with RPO expected to support this growth.
HSAI · Q4 2023 → YESThe question is about whether management describes future business that counterparties have already committed to, that's large relative to current business, with conversion expected soon. NO The transcript describes forward business through customer forecasts, order book additions, and planned SOP expansions for 2024, but does not present any committed, secured contracts or programs as "large relative to current reported business" with the required disproportion in management's own framing. Instead, it frames these as forecast-based growth and pipeline expansions, with explicit distinctions between awarded programs and RFI/RFQ opportunities.

More from the question bank

Repeat expansion inside the base while new lPhysical throughput records at the operatingConstraint-side candorFree option on their own operationsThe economics improved before the volume arrQuestions aim low, answers land highAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.